Biomarkers for Heart Failure Prediction and Prevention

Authors

Prasanti Alekhya Kotta
Vijay Nambi
Biykem Bozkurt

Publication Date

12-6-2023

Journal

Journal of Cardiovascular Development and Disease

DOI

10.3390/jcdd10120488

PMID

38132656

PMCID

PMC10744096

PubMedCentral® Posted Date

12-6-2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

heart failure, biomarkers, screening, prediction, prevention, Stage B heart failure, pre-heart failure

Abstract

Heart failure (HF) is a global pandemic affecting over 64 million people worldwide. Its prevalence is on an upward trajectory, with associated increasing healthcare expenditure. Organizations including the American College of Cardiology (ACC) and the American Heart Association (AHA) have identified HF prevention as an important focus. Recently, the ACC/AHA/Heart Failure Society of America (HFSA) Guidelines on heart failure were updated with a new Class IIa, Level of Evidence B recommendation for biomarker-based screening in patients at risk of developing heart failure. In this review, we evaluate the studies that have assessed the various roles and contributions of biomarkers in the prediction and prevention of heart failure. We examined studies that have utilized biomarkers to detect cardiac dysfunction or abnormality for HF risk prediction and screening before patients develop clinical signs and symptoms of HF. We also included studies with biomarkers on prognostication and risk prediction over and above existing HF risk prediction models and studies that address the utility of changes in biomarkers over time for HF risk. We discuss studies of biomarkers to guide management and assess the efficacy of prevention strategies and multi-biomarker and multimodality approaches to improve risk prediction.